GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

Not making COVID-19 and flu vaccines available to family physicians could adversely impact public willingness and access to ...

Dr. Victoria Weston, emergency medicine physician, Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about the difference between and emergency department and an urgent care ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.

The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.

Hay fever (also called allergic rhinitis) affects 24% of Australians. Symptoms include sneezing, a runny nose (which may feel ...

Yes, the Centers for Disease Control and Prevention (CDC) does indeed recommend the pneumococcal vaccines for pneumonia for ...